Anti-ganglioside Antibodies in Guillain-Barre Syndrome: A Novel Immunoblotting-Panel Assay

Zhu, Jiting; Zhang, Yuanyuan; Li, Runyun; Lin, Yi‐Han; Fu, Ying; Yan, Yaping; Zhu, Wei; Wang, Ning; Zhang, Zaiqiang; Xu, Guiyin

doi:10.3389/fneur.2021.760889

Cited by 7 publications

(8 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, we report the first case of the pharyngeal–cervical–brachial variant of GBS associated with COVID-19. In the AMAN variant of GBS, anti-ganglioside antibodies are found to be positive in 86% of cases [20] . While serum anti-ganglioside GM1 antibody was positive in one of our patients, there were no anti-ganglioside antibodies in our other patient.…”

Section: Discussionmentioning

confidence: 99%

Two case reports and a literature review of typical GBS and rare GBS variants associated with COVID-19

Orak

Kubur

Atasever

et al. 2023

Archives de Pédiatrie

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Two case reports and a literature review of typical GBS and rare GBS variants associated with COVID-19

Orak

Kubur

Atasever

et al. 2023

Archives de Pédiatrie

View full text Add to dashboard Cite

“…Testing for anti-ganglioside antibodies is important because they are related to the pathomechanism of GBS. A recent cohort study from China analyzed the relationship between immunemediated peripheral neuropathy and serum levels of anti-ganglioside IgG and IgM antibodies 23 . In this cohort, 42.4% patients were positive for at least one of the anti-ganglioside antibodies, and the sensitivity and specificity of the diagnostic test for GBS was 42% and 76%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Reversible conduction failure in acute inflammatory demyelinating polyneuropathy

Kim

Lee

Sohn

2022

Sci Rep

View full text Add to dashboard Cite

Reversible conduction failure (RCF) has been documented in acute motor axonal neuropathy (AMAN) and is considered a sign of nodopathy. Several reports of RCF in acute inflammatory demyelinating polyneuropathy (AIDP) have suggested that it could be a manifestation of nodopathy. We conducted this study to determine the frequency of RCF in AMAN and AIDP and to compare the clinical features between the two groups with or without RCF. RCF was observed in 38.9% and 18.5% patients in the AMAN and AIDP groups in our study, respectively. AIDP patients with anti-ganglioside antibodies represented 29.4% of the cohort. The clinical features of AIDP with RCF were more similar to those of AMAN with RCF than to those of typical AIDP. However, there were no significant differences in the frequency of anti-ganglioside antibody status between the groups. AIDP with RCF may be a manifestation of nodopathy. The current dichotomous electrodiagnostic criteria, classifying demyelinating and axonal neuropathy, are insufficient to define nodopathy. Further studies are required to revise the electrodiagnostic criteria for Guillain–Barré syndrome.

show abstract

“…Similar to the present study, GM1 antibody was reported to be common in GBS patients in several other populations, including Korean,[ 22 ] Spanish,[ 13 ] and Chinese. [ 23 ] It is important to note that the presence of GM1 antibody has been associated with the severity and prognosis of GBS. [ 24 25 ] Autoantibody against GM1 from patients with GBS was observed to impede voltage-gated calcium channels (Ca +2 v).…”

Section: Discussionmentioning

confidence: 99%

Impact of Antecedent Infections on the Antibodies against Gangliosides and Ganglioside Complexes in Guillain-Barré Syndrome

Nagappa¹,

Dutta²,

Debnath³

et al. 2022

Annals of Indian Academy of Neurology

View full text Add to dashboard Cite

Background and Aims: Guillain-Barré Syndrome (GBS), an immune-mediated neuropathy, is characterized by antibodies against gangliosides/ganglioside complexes (GSCs) of peripheral nerves. Antecedent infections have been reported to induce antibodies that cross-react with the host gangliosides and thereby have a pivotal role in conferring an increased risk for developing GBS. Data pertaining to the impact of various antecedent infections, particularly those prevalent in tropical countries like India on the ganglioside/GSC antibodies is sparse. We aimed at exploring the association between six antecedent infections and the profile of ganglioside/GSC antibodies in GBS. Methods: Patients with GBS (n = 150) and healthy controls (n = 50) were examined for the serum profile of antibodies against GM1, GM2, GD1a, GD1b, GT1b, and GQ1b and their GSCs by ELISA. These antibodies were correlated with immunoreactivities against Campylobacter jejuni , Japanese encephalitis (JE), dengue, influenza, zika, and chikungunya infections. Results: The frequencies of antibodies against six single gangliosides ( P < 0.001) and their GSCs ( P = 0.039) were significantly higher in patients as compared to controls. Except for GT1b-antibody which was more frequent in axonal GBS, none of the other ganglioside/GSC antibodies correlated with the electrophysiological subtypes of GBS. Antecedent JE infection was significantly associated with increased frequency of antibodies against GD1a, GD1b, GT1b, and GQ1b. Antibodies against GSCs were not influenced by the antecedent infections. Interpretation: This study for the first time shows an association between antecedent JE infection and ganglioside antibodies in GBS. This finding reinforces the determining role of antecedent infections on ganglioside antibody responses and the subsequent immunological processes in GBS.

show abstract

Anti-ganglioside Antibodies in Guillain-Barre Syndrome: A Novel Immunoblotting-Panel Assay

Cited by 7 publications

References 22 publications

Two case reports and a literature review of typical GBS and rare GBS variants associated with COVID-19

Two case reports and a literature review of typical GBS and rare GBS variants associated with COVID-19

Reversible conduction failure in acute inflammatory demyelinating polyneuropathy

Impact of Antecedent Infections on the Antibodies against Gangliosides and Ganglioside Complexes in Guillain-Barré Syndrome

Contact Info

Product

Resources

About